Search

Your search keyword '"Mu, Zhaomei"' showing total 69 results

Search Constraints

Start Over You searched for: Author "Mu, Zhaomei" Remove constraint Author: "Mu, Zhaomei" Database Unpaywall Remove constraint Database: Unpaywall
69 results on '"Mu, Zhaomei"'

Search Results

6. Supplementary Figure S4: ATF3 represses AR transcriptional target PSA expression in LNCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity

7. Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity

8. Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity

12. Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

13. Data from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

14. Data from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

15. Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

16. Legends of Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

17. Supplementary Table S1. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

18. Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

19. Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

20. Supplementary Table S2. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

21. Supplementary Table S2. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

22. Legends of Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

23. Supplementary Table S3. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

24. Supplementary Table S3. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

25. Supplementary Table S1. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

26. Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer

28. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors

29. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA

30. Abstract 2646: The liquid biopsy network in advanced breast cancer (ABC): Benchmarking the prognostic role of circulating tumor DNA (ctDNA) to the goal standard circulating tumor cells (CTCs) enumeration

31. Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IVprog).

32. CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

33. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

36. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone

37. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer

40. Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).

41. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.

42. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer

44. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study

46. Abstract 2788: Comprehensive high-depth target sequencing in circulating tumor DNAs of patients with inflammatory and non-inflammation breast cancers

Catalog

Books, media, physical & digital resources